Eisai Clinical Trials

A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma


Study Overview

eribulin mesilate
NCT01327885, EU CTR 2010-024483-17
Mar 2011 - Jan 2015
Soft Tissue Sarcoma
Overall survival (OS)

  • Males and females (age 18 years and over)

  • Completed

  • Phase 3

  • Argentina, Australia, Austria, Belgium, Brazil, Canada, Czech Republic, Denmark, France, Germany, Israel, Italy, Korea, Republic of, Netherlands, New Zealand, Poland, Romania, Russian Federation, Singapore, Spain, Thailand, United Kingdom, United States See more


CSR Synopsis

Download PDF

Lay Summary

Download PDF
Publication reference citation

Schöffski P, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. The Lancet 2016 Apr 16;387(10028):1629-37. DOI: 10.1016/S0140-6736(15)01283-0

Data Sharing

ClinicalStudyDataRequest.com (CSDR) is a multi sponsor site through which qualified researchers who wish to access clinical trial data and associated information in order to conduct further research can submit their research proposal or enquiry.

Redacted documents are available upon request for this study.

Document type Availability
Sample CRF
Full CSR